Good morning folks, in case you missed it the following articles appeared in the September 2014 print edition of HCV Next published online at Healio.
"HCV Next" offers information on a range of topics, which include diagnosis, new combination therapies, side effects, drug/drug interaction, guidelines, fatty liver disease and more.
COVER STORY
The Challenge of Genotype 3
For many clinicians, genotype 3 now presents the greatest challenge in the treatment and management of patients with hepatitis C virus.
In a recent paper published in the Journal of Viral Hepatology, HCV Next Editorial Board member Nezam H. Afdhal, MD, and Elliot B. Tapper, MD, from Beth Israel Deaconess Medical Center, called genotype 3 “potentially the most difficult-to-treat genotype and an area of intense research for new drug development.”
For many clinicians, genotype 3 now presents the greatest challenge in the treatment and management of patients with hepatitis C virus.
In a recent paper published in the Journal of Viral Hepatology, HCV Next Editorial Board member Nezam H. Afdhal, MD, and Elliot B. Tapper, MD, from Beth Israel Deaconess Medical Center, called genotype 3 “potentially the most difficult-to-treat genotype and an area of intense research for new drug development.”
EDITORIAL
Ira M. Jacobson, MD
HCV RX
Challenges with Pharmacotherapy of HCV/HIV Coinfection
Hepatitis C virus infection is common among individuals already infected with HIV, affecting about one-third of patients. Experts anticipate this number may increase given the shared risk factors for acquisition of both infections. In fact, a proportional rise in the sexual transmission of HCV has been observed since antiretroviral therapy (ART) became widely available in the mid-1990s, possibly reflecting longer duration and improved quality of life, and perhaps a perception of fewer risks associated with unprotected sexual intercourse while receiving treatment for HIV. However, blood exposure remains the most efficient mode of infection, which explains the very high incidence, more than 90%, of HCV coinfection and injection drug use in the HIV-positive population.
TREND WATCH
Gaps in HCV Care Identified in US
First All-Oral Interferon- and Ribavirin-Free HCV Therapy Approved in Japan
Bristol-Myers Squibb announced in July that the Japanese Ministry of Health, Labor and Welfare approved daclatasvir, a potent, pan-genotypic NS5A replication complex inhibitor, and asunaprevir, an NS3/4A protease inhibitor, for patients with hepatitis C virus.
The Daklinza and Sunvepra Dual Regimen is Japan’s first all-oral, interferon- and ribavirin-free treatment option for patients with HCV genotype 1 infection, including those with compensated cirrhosis, according to a press release.
Genotype 1 Most Prevalent Worldwide
Hepatitis C virus genotype 1 is the most prevalent genotype and accounts for 83.4 million infections, or 46.2% of all cases, worldwide, according to a study published in Hepatology.
MK-5172 with PEG-IFN/Ribavirin, Effective, Safe
The protease inhibitor MK-5172 in combination with pegylated interferon and ribavirin was safe and effective for the treatment of patients with hepatitis C virus without cirrhosis.
Patients with HIV, HCV Showed Spontaneous HCV Clearance during ART
Three patients with hepatitis C virus and HIV coinfection spontaneously became negative for HCV RNA while undergoing antiretroviral therapy, and all had the IL28B CC genotype, researchers in Sweden reported.
PHOTON-1: Sofosbuvir, Ribavirin Combo Yielded High SVR in Coinfected Patients
A majority of treatment-experienced and treatment-naive patients with hepatitis C virus and HIV coinfection achieved sustained virologic response after treatment with combination sofosbuvir and ribavirin, according to results from the PHOTON-1 study published in JAMA.
Study Predicts HCV Will Become Rare Disease by 2036
Effective drugs and screening could make hepatitis C virus a rare disease in the United States by 2036.
In this issue, HCV Next asks five questions of Camilla S. Graham, MD, MPH, assistant professor of medicine at Beth Israel Deaconess Medical Center and Harvard Medical School.
HCV Next Now Delivered Monthly
This has been a landmark year for the care of patients with hepatitis C virus. The development of new drugs is rapidly changing the treatment landscape and important news is released almost daily about different regimens and combinations, improved protocols and screening processes, and more.
This has been a landmark year for the care of patients with hepatitis C virus. The development of new drugs is rapidly changing the treatment landscape and important news is released almost daily about different regimens and combinations, improved protocols and screening processes, and more.
FEATURE
A Goal to Improve the Continuum of HCV Care
New treatment options and mandated screening of baby boomers should translate into a flood of new patients with hepatitis C virus entering the health care system, but adoption of new guidelines is often slow in health care. With a goal of achieving sustained virologic response in as many people living with hepatitis C virus as possible, the clinical community faces the challenge of identifying and keeping them engaged in the health care system, from initial visits through the cure of infection.
A Goal to Improve the Continuum of HCV Care
New treatment options and mandated screening of baby boomers should translate into a flood of new patients with hepatitis C virus entering the health care system, but adoption of new guidelines is often slow in health care. With a goal of achieving sustained virologic response in as many people living with hepatitis C virus as possible, the clinical community faces the challenge of identifying and keeping them engaged in the health care system, from initial visits through the cure of infection.
THE BIG PICTURE
HCV: A Systemic Disease with Extrahepatic Features
Hepatitis C virus infection is known to be associated with chronic hepatitis, cirrhosis and hepatocellular carcinoma. However, HCV can have serious consequences for other organ systems as well. Extrahepatic HCV-associated disorders include cardiovascular, central nervous system, dermatological, endocrine, renal and rheumatologic diseases.
HCV: A Systemic Disease with Extrahepatic Features
Hepatitis C virus infection is known to be associated with chronic hepatitis, cirrhosis and hepatocellular carcinoma. However, HCV can have serious consequences for other organ systems as well. Extrahepatic HCV-associated disorders include cardiovascular, central nervous system, dermatological, endocrine, renal and rheumatologic diseases.
Ira M. Jacobson, MD
HCV RX
Challenges with Pharmacotherapy of HCV/HIV Coinfection
Hepatitis C virus infection is common among individuals already infected with HIV, affecting about one-third of patients. Experts anticipate this number may increase given the shared risk factors for acquisition of both infections. In fact, a proportional rise in the sexual transmission of HCV has been observed since antiretroviral therapy (ART) became widely available in the mid-1990s, possibly reflecting longer duration and improved quality of life, and perhaps a perception of fewer risks associated with unprotected sexual intercourse while receiving treatment for HIV. However, blood exposure remains the most efficient mode of infection, which explains the very high incidence, more than 90%, of HCV coinfection and injection drug use in the HIV-positive population.
TREND WATCH
Gaps in HCV Care Identified in US
First All-Oral Interferon- and Ribavirin-Free HCV Therapy Approved in Japan
Bristol-Myers Squibb announced in July that the Japanese Ministry of Health, Labor and Welfare approved daclatasvir, a potent, pan-genotypic NS5A replication complex inhibitor, and asunaprevir, an NS3/4A protease inhibitor, for patients with hepatitis C virus.
The Daklinza and Sunvepra Dual Regimen is Japan’s first all-oral, interferon- and ribavirin-free treatment option for patients with HCV genotype 1 infection, including those with compensated cirrhosis, according to a press release.
Grant Aids Researchers Studying Patients Cured of HCV
Doctors from the Perelman School of Medicine at University of Pennsylvania and Massachusetts General Hospital will co-direct a $12 million grant to study patients who have been effectively cured of hepatitis C virus infection.
Doctors from the Perelman School of Medicine at University of Pennsylvania and Massachusetts General Hospital will co-direct a $12 million grant to study patients who have been effectively cured of hepatitis C virus infection.
Therapeutic advances in the treatment of hepatitis C virus infection have greatly increased a patient’s chance for a cure and at a faster rate, according to a consumer update from the FDA.
Genotype 1 Most Prevalent Worldwide
Hepatitis C virus genotype 1 is the most prevalent genotype and accounts for 83.4 million infections, or 46.2% of all cases, worldwide, according to a study published in Hepatology.
MK-5172 with PEG-IFN/Ribavirin, Effective, Safe
The protease inhibitor MK-5172 in combination with pegylated interferon and ribavirin was safe and effective for the treatment of patients with hepatitis C virus without cirrhosis.
Patients with HIV, HCV Showed Spontaneous HCV Clearance during ART
Three patients with hepatitis C virus and HIV coinfection spontaneously became negative for HCV RNA while undergoing antiretroviral therapy, and all had the IL28B CC genotype, researchers in Sweden reported.
PHOTON-1: Sofosbuvir, Ribavirin Combo Yielded High SVR in Coinfected Patients
A majority of treatment-experienced and treatment-naive patients with hepatitis C virus and HIV coinfection achieved sustained virologic response after treatment with combination sofosbuvir and ribavirin, according to results from the PHOTON-1 study published in JAMA.
Study Predicts HCV Will Become Rare Disease by 2036
Effective drugs and screening could make hepatitis C virus a rare disease in the United States by 2036.
5 QUESTIONS
No comments:
Post a Comment